“what’s the evidence for-”

A great review on post-renal transplant erythrocytosis to add to the differential! Surprisingly occurs in 10-15% of cases https://t.co/8jiXPdgi4s

Daratumumab monotherapy may be an effective and well-tolerated treatment in more than half of patients with refractory AIHA and cold agglutinin disease. https://t.co/CZ2eUSZz7r #clinicaltrialsandobservations #immunobiologyandimmunotherapy

Great talk at #EHA2024 surrounding current challenges in MF and AML. Interesting discussion on the uncertainty in optimal consolidation strategies in MRD+ AML and timing of transplant in MF

Interesting article from The Atlantic on a great topic! @RazaSN https://t.co/ZyjrYvHh4J

Half way through the second CTU block of PGY2 and I am reminded by the heterogeneity in presentations of lymphopoliferative disorders! A great review on splenic MZL, intriguing to learn that it was first described as recently as 1992 (PMID: 1599024) https://t.co/XCLv7bTG3e

Sunny Days on Yellow Team @elliotchsmith @garwayma @HodaSeragMD Roya Rastegar & Emma Sparks. An absolute pleasure to work with such a wonderful team. Photography by @CPSkorupski @UofT_DoM

Extremely grateful to receive the @ASH_hematology HONORS award! Thank you to my mentors including Dr. Dawn Maze for their support and helping me expand upon a topic I am incredibly passionate about. #ASHAwards

RIP Gary Rossington of @Skynyrd Here's my 2002 @VH1 doc on the band (yes, I’m cringe but the doc holds up) Too many of the brilliant musicians in the doc are no longer with us! https://t.co/mRgYFuvgxe

Pink Floyd released their classic album "Dark Side Of The Moon", March 1, 1973. Favorite track?

3 blocks of TGH CTU down, only 1 to go! How are we over half way done PGY2 already? So lucky to have such a big team (with some missing) and also to get to do so much teaching with our learners and PA’s.

2/ When do you start AC for new Afib post-op? We hope this infographic will be handy for the many times we may be in the gray zone! From @accpchest guidelines A few things to consider: 🤔 Patient specific risk 🤔 Blood thinner of choice 🤔 Bleeding risk of the surgery

Indications for and Timing of Initiation of KRT ca. 2023 from @CJASN @MarliesOsterman @drseanbagshaw @DrRonWald #Nephpearls #AKIinICU https://t.co/AzllUlLznl

Why did Claude Monet paint the same water lilies in his garden more than 250 times? Well, for Monet, they were different every time...

New #InTheClinic: Monoclonal Gammopathy of Undetermined Significance https://t.co/yV3WFbXt6W

Hey #MedTwitter! Do the words "culture change" come up often when thinking about your internal medicine program? What does "culture" even mean? We're looking at that very question for our #qualitativeresearchproject.

Picture this: A patient presents with a headache, and you find this 👇 on your evaluation. Why (and how) is this an emergency? 🧵 1/8

This is such a good question because it illustrates something that happens a lot in the heme precursor space: the conflation of clinical/public health interested with research interests. Here are my thoughts on the matter 🧵

In smouldering MM, determining who benefits from treatment is an ongoing debate. Recommendations for high risk patients with incorporation of dynamic biomarker testing that is being validated

Great #ASH22 session on treating myeloma in 2022. In MGUS, helpful predictive tools to evaluate need for bone marrow biopsy and assess for >10% BM plasma cell percentage. 1/ https://t.co/oI9uSOnGO4